Dexcom CGM now funded for Type 1 diabetes under Pharmac. Learn more
Our products
t:slim X2™ Insulin Pump with Control-IQ™ Technology
The pump that gets updated, not outdated. The simple-to-use t:slim X2 insulin pump has a slim and sleek design and packed with big features.
Dexcom Continuous Glucose Monitoring Systems
Easy, accurate‡ and better health outcomes.1-5 Manage your diabetes with zero fingerpricks.* Stay on track to be your best with Dexcom G7 and Dexcom ONE+.
Dexcom Clarity
Our Warrior Community
With over 20,000 Dexcom Warriors globally, Warriors are Dexcom CGM customers with inspiring stories who want to share their experiences with others – whether that be balancing their glucose levels whilst working the 9 to 5, competing in their chosen sport/profession at an elite level or perhaps progressing with their goals such as completing university degrees or adventurous treks. This program is supported by NZMS Diabetes.
Our Events
Our aim is to provide our customers and healthcare professionals with the best products and support. That’s why we’re always hosting events across the country. Whether you want to find out more about our products, get some great tips on diabetes management or just meet some great people, we have an event for you.
Always read the label and use only as directed. Read the warnings available on nzmsdiabetes.co.nz/resources before purchasing. Consult your healthcare professional to see if this product is right for you.
The Tandem t:slim X2 insulin pump with Control-IQ technology provides continuous delivery of insulin through a subcutaneously applied infusion set. The algorithm will adjust insulin delivery according to the predicted glucose when used with a compatible CGM. The Tandem t:slim Mobile App is an accessory intended for use as a connected software device that is able to reliably and securely communicate with compatible insulin pumps. Dexcom G7 and ONE+ are continuous glucose monitoring systems indicated for the management of (type 1, type 2, gestational) diabetes in people age 2 years and older where self-monitoring of blood glucose (SMBG) is indicated. Dexcom Clarity is a web-based device intended for use by both home users and healthcare professionals to assist people with diabetes in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. The device does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the device. Healthcare professionals should use information in the device in conjunction with other clinical information available to them.
*If your glucose alerts and readings from the Dexcom G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions; † Smart device sold separately. To view a list of compatible devices, visit nzmsdiabetes.co.nz/mobile-compatibility; § As compared to Dexcom G6 System.
References: 1 Beck RW, et al. JAMA. 2017;317(4):371-378; 2 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374; 3 Martens T, et al. JAMA. 2021;325(22):2262-2272; 4 Laffel LM, et al. JAMA. 2020;323(23):2388-2396; 5 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7.
© 2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Control-IQ, and t:slim X2 are registered trademarks or trademarks of Tandem Diabetes Care, Inc. Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom G7, Dexcom ONE+, Dexcom Share, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. © 2025 Dexcom, Inc. New Zealand Medical & Scientific Limited is a Dexcom company. 2A Fisher Crescent, Mount Wellington, Auckland 1060.
Always read the label and use only as directed. Read the warnings available on nzmsdiabetes.co.nz/resources before purchasing. Consult your healthcare professional to see if this product is right for you.
The Tandem t:slim X2 insulin pump with Control-IQ technology provides continuous delivery of insulin through a subcutaneously applied infusion set. The algorithm will adjust insulin delivery according to the predicted glucose when used with a compatible CGM. The Tandem t:slim Mobile App is an accessory intended for use as a connected software device that is able to reliably and securely communicate with compatible insulin pumps. Dexcom G7 and ONE+ are continuous glucose monitoring systems indicated for the management of (type 1, type 2, gestational) diabetes in people age 2 years and older where self-monitoring of blood glucose (SMBG) is indicated. Dexcom Clarity is a web-based device intended for use by both home users and healthcare professionals to assist people with diabetes in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. The device does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the device. Healthcare professionals should use information in the device in conjunction with other clinical information available to them.
*If your glucose alerts and readings from the Dexcom G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions; † Smart device sold separately. To view a list of compatible devices, visit nzmsdiabetes.co.nz/mobile-compatibility; ‡ Bolus delivery from the Tandem t:slim mobile app requires a compatible smartphone model and operating system, software version 7.8.1 onwards on the t:slim X2 insulin pump and additional training; § As compared to Dexcom G6 System.
References: 1 Beck RW, et al. JAMA. 2017;317(4):371-378; 2 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374; 3 Martens T, et al. JAMA. 2021;325(22):2262-2272; 4 Laffel LM, et al. JAMA. 2020;323(23):2388-2396; 5 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7.
© 2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Control-IQ, and t:slim X2 are registered trademarks or trademarks of Tandem Diabetes Care, Inc. Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom G7, Dexcom ONE+, Dexcom Share, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. © 2025 Dexcom, Inc. New Zealand Medical & Scientific Limited is a Dexcom company. 2A Fisher Crescent, Mount Wellington, Auckland 1060.